This new report is an update of our regular report, "Cancer Vaccine Industry", which focuses on a segment of cancer vaccine companies. It delivers advanced market profiling, interactive mindmaps, information about companies and investors, technology application use cases and other actionable information.

The current report version reviewed the cancer vaccine platforms: Neoantigen Platform, Tumor-associated Antigens Platform, Cellular Platform, and Oncolytic Viruses Platform — and the latest breakthrough and a potentially disruptive research strategy — Antigenic Essence Platform, which is actively developing its products to enter the market of immunotherapy. Additionally, we have added a new chapter about cancer vaccine delivery systems, which is now a hot topic in biotechnology. As a result, we assessed more than 450 investors, 200 companies and R&D centres and a detailed analysis of more than 30 of them.